In this exclusive session, Stephanie Piekos, PhD, Senior Scientist at Boehringer Ingelheim, shares insights into the challenges of evaluating AO substrates and how more predictive, human-relevant models are shaping the future of DMPK studies.
Understanding aldehyde oxidase (AO)-mediated metabolism has become increasingly critical in drug development, as traditional models often fail to capture this non-CYP clearance pathway with sufficient accuracy. Join us to explore how TruVivo®—LifeNet Health’s all-human 2D+ hepatic system—delivers enhanced AO activity compared to conventional in vitro models. With improved enzyme stability and metabolic function over extended culture periods, TruVivo offers a powerful platform for identifying metabolic liabilities, predicting human clearance, and bridging translational gaps in early development. This session is a must for scientists focused on advancing preclinical models for more accurate and reliable decision-making.
Key Topics Include:
- Understand the metabolic role and clinical importance of aldehyde oxidase
- Recognize the limitations of traditional models for studying AO-mediated clearance
- Discover how TruVivo enhances AO activity to support more predictive, human-relevant outcomes
- Categories: Cell & Molecular Biology, Drug Discovery & Development, Pharmacology, Toxicology
- Tags: cell metabolism, drug development, drug discovery, drug metabolism, drug testing, drug-drug interaction, hepatocytes, human biological sample (HBS), human cells, liver, Mammalian cell culture, pharmacokinetics, pharmacology, safety pharmacology, toxicology
Presenters
Stephanie Piekos, PhD
Principal Scientist
Nonclinical Drug Metabolism and Pharmacokinetics Group
Boehringer Ingelheim
Stephanie is currently a Principal Scientist in the Nonclinical Drug Metabolism and Pharmacokinetics group at Boehringer Ingelheim in Ridgefield, Connecticut.
Production Partner
LifeNet Health LifeSciences
LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.
Additional Content From LifeNet Health LifeSciences
Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model
Learn how an emerging NAM is helping advance more efficient, human-relevant strategies for assessing thyroid hormone disruption while reducing reliance on animal testing.
Integrating Regulatory Guidance and Sustainable Skin Procurement for Consistent Execution of In Vitro Permeation Testing
Join LifeNet Health LifeSciences for our first Assay Services webinar, focusing on Dermal Absorption. This session explores in vitro permeation testing, a crucial method for assessing a compound’s potential to penetrate the skin and reach systemic circulation.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research
Get an exclusive first look at BrainXell’s newly launched human iPSC-derived sensory neurons and learn how they enable reproducible, human-relevant models for sensory transduction, pharmacology, and ion channel research.
Protein-Protein Interaction (PPI) Landscape – Sequence-to-Affinity Heatmaps for High-Throughput Antibody Optimization
In this webinar, Dr. Jihye Jo introduces PPI (protein-protein interaction) Landscape, powered by PROTEINA’s single-molecule SPID platform.
